Insider trade

CEO sold ~$79K of GILD shares in the open market

Traded Aug 3, 2026 · Filed Aug 4, 2026

Gilead SciencesGILD

~$79K
Reported value · 600 sh @ $131.3433: 592K
Holds after · shares reported: +12.5%
stock since the trade · S&P 500 +0.8%, $131.15 → $147.50 on Oct 1

Why it stands out

The boss of Gilead Sciences sold $79K of Gilead Sciences shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 3, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 4, 2026

CEO$25K–$100KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$78,806

Shares × reported transaction price

Timing vs results

88 days after results of May 7, 2026, 1 day before results of Aug 4, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $131.15 on Aug 3, 2026, 19% above its 52-week low and 16% below its high, after a 6% rise over the previous 30 trading days

52-week range $110.28 (Aug 6, 2025) to $155.80 (Feb 11, 2026), 46% of the way up, from 251 adjusted closes. 30 trading days earlier: $123.76 on Jun 18, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Bixlenvo on Aug 27, 2026, 24 days after this trade.

New drug application approved. Active ingredient: Bictegravir Sodium, Lenacapavir Sodium. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+3.1%	+0.3%	+2.8%
30 days	+14.6%	+0.1%	+14.6%

Past results only. Not a forecast.

Source receipt

Record ID: 0001638643-26-000028
Filed / recorded: Aug 4, 2026, 9:40 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: GILEAD SCIENCES, INC.
Issuer CIK: 882095
Ticker: GILD
Reporting person: Daniel Patrick O'day
Relationship: Director, Officer
Officer title: Chairman & CEO
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Aug 3, 2026
Transaction code: S
Shares / units: 600
Price per share: $131.3433
Acquired / disposed: Disposed (D)
Shares owned after: 592,133
Ownership form: Direct
Amendment: No

Footnotes from the filing

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
Sale prices for the transactions reported range from $131.21 to $131.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Around the same time

CEO sold ~$236K of Gilead Sciences

Scheduled in advance5w ago

CEO sold ~$1.19M of Gilead Sciences

Scheduled in advance5w ago

CEO sold ~$808K of Gilead Sciences

Scheduled in advance5w ago

Why it stands out

Dates, kept separate

Context

After it was reported

Source receipt

Footnotes from the filing

Around the same time

Most active this month